Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Liabilities and Shareholders Equity (2016 - 2025)

Lipocine's Liabilities and Shareholders Equity history spans 14 years, with the latest figure at $16.1 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 22.35% year-over-year to $16.1 million; the TTM value through Sep 2025 reached $77.7 million, down 15.75%, while the annual FY2024 figure was $22.5 million, 2.13% down from the prior year.
  • Liabilities and Shareholders Equity reached $16.1 million in Q3 2025 per LPCN's latest filing, down from $18.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $52.5 million in Q4 2021 to a low of $16.1 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $32.4 million, with a median of $30.5 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 140.93% in 2021, then plummeted 38.73% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $52.5 million in 2021, then decreased by 28.47% to $37.5 million in 2022, then tumbled by 38.73% to $23.0 million in 2023, then decreased by 2.13% to $22.5 million in 2024, then fell by 28.6% to $16.1 million in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Liabilities and Shareholders Equity are $16.1 million (Q3 2025), $18.6 million (Q2 2025), and $20.5 million (Q1 2025).